Skip to main content

Advertisement

Journal news

A Letter from Johnson Mak

It is with mixed emotions that I am writing this letter to inform you of some changes to  Retrovirology.

It is such a blessing that Retrovirology has had such great scientists involved in guiding the journal from its inception. On the one hand, it is sad for me to inform you that after nearly 15 years of service with Retrovirology (~10 years as Founding Associate Editor and ~6 years as co-Editor-in-Chief), our friend Prof Andrew Lever will be stepping down from his role of co-Editor-in-Chief in Retrvoriology as of 30th April 2019. Andrew will remain as an editorial member of our journal. Andrew has made tremendous contributions to retrovirus related research, in particular in the area of RNA, and is continuously revealing novel insights of retrovirus biology. More recently, Andrew has combined his passions toward both RNA biology and clinical practice to better understand HIV cure research. I understand there will be some interesting stories on their way. I will certainly miss Andrew’s regular guidance and support. (Andrew, I hope you do not mind that I probably will continue seek your advice from time to time.)I hope that you will join me to express our appreciation to Andrew for his service to Retrovirology.

They say that when one door closes, another door opens. This is very true for Retrovirology at this point in time. I am delighted to announce that an equally impressive researcher in our field has agreed to step in to become our next co-Editor-in-Chief, and this is Prof Susan R Ross (Sweeney Basic Sciences Professor and Head at Department of Microbiology and Immunology, College of Medicine, University of Illionis). We all know Susan as a world renowned retrovirologist with strong interest in both mouse retroviruses and other rodent viruses – including arenaviruses like Junin virus. I must admit that I learnt more about Susan’s back story through an interesting read from a recent featured article on Susan in PLoS Pathogens. I hope that you will join me in welcoming Susan to the editorial team in Retrovirology.

Andrew, Susan and I are working on a few other possibilities to enhance our journal. Hopefully, we will be able to share some of these exciting news with you all when they become available.

Johnson Mak

Andrew Lever, Editor Emeritus

Prof Andrew Lever has been with Retrovirology since it's founding 15 years ago, so it is great sadness we announce he has retired from his role as Editor-in-Chief, but it is also a great honour to announce that he will continue his association with the journal as Editor Emeritus. 

He leaves the team in a strong position at the heart of it's community. 

We would like to thank him for all his efforts with the journal, helping shape the journal as it begins it's new era and a bright future.

Graphical Abstracts

We are pleased to announce that Retrovirology is accepting articles with graphical abstracts, capturing the articles content in a single image for our readers. For more information, please see our Submission Guidelines.

New American Society for Microbiology Fellows

We would like to congratulate many of our  colleagues who have been elected to be fellows of American Society for Microbiology and American Association for the Advancement of Science. Amongst the 109 newly elected fellows, there included a number of Retrovirology's board members and others who have made important contributions to the field of retrovirology, including:

  • Galit Alter, Ph.D., Massachusetts General Hospital, Harvard Medical School
  • Michael Farzan, Ph.D., Scripps Research Institute, Florida Campus
  • Eric Freed, Ph.D., National Cancer Institute, NIH (Editorial Board Member of Retrovirology)
  • Jeffrey  Lifson, Ph.D., NCI-Frederick Cancer Research
  • Harmit  Malik, Ph.D., Fred Hutchinson Cancer Research Centre 
  • John Schmitz, Ph.D., University of North Carolina Hospitals
  • Viviana Simon, M.D., Icahn School of Medicine at Mount Sinai (Editorial Board Member of Retrovirology)
  • Richard Zhao, Ph.D., University of Maryland School of Medicine (Editorial Board Member of Retrovirology)

The KT Jeang Retrovirology prize 2018

New Content ItemRetrovirology awards the annual KT Jeang Retrovirology Prize to recognize outstanding achievements in the field by mid-career scientists.

It is with great pleasure that we announce the 2018 winner: Eric Freed. An editorial briefly outlining the winner's achievements has been published here

Past winners are: S. Goff (2005), J. Sodroski (2006), K. Beemon (2007), B. Berkhout (2008), T. Heidman (2009), M. Malim (2010), M. Matsuoka (2011), M. Benkirane (2013), P. Bieniasz (2015), F. Kirchhoff (2016), and M. Emerman (2017).

Closing out 2017

As we near the end of an eventful year, both globally and for Retrovirology, it is fitting to announce at this time new developments for the journal. We say goodbye and a deeply felt thank you to Robin Weiss as Reviews Editor and welcome in his place Frank Kirchhoff who will be known to many of you and was a recent winner of the Retrovirology annual prize. Frank brings with him a wealth of high quality research experience in HIV. He has already begun to assemble a new thematic review series for the journal to follow on from the two that have begun to be published this year on HIV Latency (edited by Ben Berkhout and Alexander Pasternak) and Disruptive technologies in retrovirus research (edited by Johnson Mak).  

In another welcome addition to our team we are delighted to announce that David Margolis has joined as an Associate Editor. David is a leading expert in HIV latency and approaches to HIV cure which we all hope to be a topic that features strongly in Retrovirology in the coming few years. Read more about our two new Editors below. 

On these optimistic notes we thank all our contributors and reviewers and look forward to an exciting 2018!

New Content ItemProf. Dr. Frank Kirchhoff trained in Biology at the Georg-August-University in Göttingen and subsequently carried out his Diploma thesis at the German Primate Center in Göttingen. Thereafter, he performed post-doctoral training with Prof. Dr. Ronald Desrosiers at the NERPRC, Harvard Medical School, Boston. From 1994 to 2001, he was Lab Head of the Department of Virology at the University of Erlangen. In 2001, he joined the Institute of Virology at Ulm University Medical Center to become Associate Professor. Since 2009, he is Director of the newly funded Institute of Molecular Virology at Ulm University. His main interests are the pathogenesis of HIV/AIDS as well as innate immune defenses and mechanisms of viral evasion or counteraction by the viral accessory Vpu, Vpr and Nef proteins. Furthermore, the Kirchhoff group is interested in the discovery of novel endogenous factors affecting HIV and SIV infection and their optimization for basic research or clinical application.

New Content ItemProfessor David Margolis became interested in HIV as the pandemic emerged during his medical training. Trained at Tufts, the New England Medical Center, the Laboratory of Clinical Investigation at the NIH, and Program in Molecular Medicine at UMass, he has cared for people with HIV and studied the interactions between HIV and the host cell on the molecular level for his entire career. For nearly 2 decades, he and many collaborators have begun to understand the molecular basis of HIV latency, develop drug and immunotherapy approaches to target persistent HIV, to develop the tools needed to cure HIV infection.  He is the director of the UNC HIV Cure Center, funded in part by a public-private partnership between UNC and GlaxoSmithKline, principal investigator for the NIH-sponsored Collaboratory of AIDS Researchers for Eradication (http://www.delaneycare.org), and a professor of Medicine, and Microbiology & Immunology at the University of North Carolina at Chapel Hill.

19 December 2017

HIV cure – what does it mean?

In honor of World AIDS Day 2017, Dr Andrew Lever discusses the possibilities and complexities of a cure for HIV in this BMC On Medicine blog.

December 1st 2017 is the 30th anniversary of World AIDS Day. This year's theme is “Increasing Impact through Transparency, Accountability, and Partnerships”, reflecting how to increase our impact to move epidemics from crisis toward control. 
Read more from across BMC

1 December 2017

Welcome to new Editor-in-Chief Johnson Mak

We are delighted to announce that Dr Johnson Mak has been appointed Co-Editor-in-Chief of Retrovirology. Dr Mak is a well-known and highly respected figure in the retroviral field. He has been an Editor with the journal since 2004. Johnson brings a broad research expertise in HIV to the position as well as having a successful track record in scientific publishing.

 - Andrew Lever

24 July 2017

The KT Jeang Retrovirology prize 2017

Retrovirology awards the annual KT Jeang Retrovirology Prize to recognise outstanding achievements in the field by mid-career scientists, older than 45 but younger than 60. Nominees are evaluated by the Retrovirology Editors in what is always a very tight contest. The winner, who receives a trophy and a cheque of 2000 GBP, is announced in the journal with an accompanying editorial that briefly outlines the winner's achievements. Although we maintain strict confidentiality about nominees who did not win, many of them are also outstanding scientists who may well receive the prize in the future, testament to how much the Retrovirology Prize is truly valued by our community.

Past winners are: S. Goff (2005), J. Sodroski (2006), K. Beemon (2007), B. Berkhout (2008), T. Heidman (2009), M. Malim (2010), M. Matsuoka (2011), M. Benkirane (2013), P. Bieniasz (2015) and F. Kirchhoff (2016).

It is with great pleasure that we announce the 2017 winner: Michael Emerman.

Read this year's Editorial or view all previous winners.

26 June 2017

Welcome to new Associate Editor François Venter

We are delighted to welcome Professor François Venter to the Editorial team of Retrovirology. Professor Venter has been Associate Professor at the School of Clinical Medicine at the University of the Witwatersrand since 2009 and Deputy Executive Director of the Wits Institute, School of Clinical Medicine, University of the Witwatersrand since 2010. He has published extensively on clinical issues of pathogenesis and treatment of HIV/AIDS and he brings with him a vast wealth of clinical experience as well as an invaluable knowledge of HIV in resource poor settings. He broadens the subject expertise and the geographical reach of the journal and will be the focus for the extension of the remit of Retrovirology into the clinical arena. We look forward to combining the established expertise and high standards in laboratory research in retroviruses of our current editorial team with the exciting areas of clinical research where so many advances are now occurring and the word ‘cure’ is just starting to be mentioned in a more serious manner than ever has been the case previously.

23 May 2017

Dr Mark Wainberg

The Editors and Publisher of Retrovirology regret to announce the death of Dr Mark Wainberg, founding editor and latterly co-Editor-in-Chief.

 

All at the Journal wish to express their deepest sadness at his passing and send their condolences to his family and many close friends. You can read our obituary for Mark here.

14 April 2017

Frontiers of Retrovirology 2016

Read the full proceedings of the meeting's oral presentations, covering topics from 'innate sensing and intrinsic immunity' to 'adaptive immunity' and 'recent advances in HIV vaccine development'.

5 October 2016

Annual Journal Metrics

Advertisement